$ARWR Income Statement | Understand Stock

$ARWR

$59.03 +$0.00 (0.0%) After hours

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Sep 30, 2025	FY2024 12 months to Sep 30, 2024	FY2023 12 months to Sep 30, 2023	FY2022 12 months to Sep 30, 2022	FY2021 12 months to Sep 30, 2021
Revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Operating income (loss)
Other (expense) income:
Interest income
Interest expense
Other, net
Total other expense
Income (loss) before income tax expense and noncontrolling interest
Income tax expense (benefit)
Net income (loss) including noncontrolling interest
Net income (loss) attributable to noncontrolling interest, net of tax
Net loss attributable to Arrowhead Pharmaceuticals, Inc.
Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:
Basic (in dollars per share)
Diluted (in dollars per share)
Weighted-average shares used in calculating
Basic (in shares)
Diluted (in shares)
Other comprehensive loss, net of tax:
Unrealized gains (losses) on available-for-sale securities
Foreign currency translation adjustments
COMPREHENSIVE INCOME (LOSS)
Comprehensive income (loss) attributed to noncontrolling interest
Other comprehensive income (loss)

Comments